B+
Bull case
25%
Probability
Target price
$1.00
Analysis reference price unavailable
Analysis 2026-09-11 · RankAlpha Sentiment Codex
BEAT
HeartBeamANasdaq / Health Care Equipment & Services
Last Price
Quote time unavailable
Current thesis
Successful TCT data, constructive FDA feedback and conversion of pilot agreements into recurring orders could materially improve validation for HeartBeam's synthesized 12-lead ECG platform. Cost reductions and reported runway into 2027 provide some time to reach these milestones, although the runway claim comes from stored third-party earnings coverage rather than a confirmed company release.
Posture
Constructive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite.
What can break
Commercial traction remains early; initial shipments, pilot agreements and positive feedback do not establish recurring revenue or scalable adoption.
Momentum
100
Value
37
Sentiment
94
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $0.50 · Bull $1.00 · Bear $0.20Analysis 2026-09-11; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-10 • Model: HYBRID_IC_RP
AI Memo
As of 2026-09-11 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-10
Investment thesis
As of 2026-09-10
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-10. Definitions
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $3.50
Why
Momentum100 · Δ7d -
Value37 · Δ7d -0.0
Sentiment94 · Δ7d -
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Confirming evidence
- • Sentiment remains the lead driver in the composite.
Contradictions & invalidation
- • Commercial traction remains early; initial shipments, pilot agreements and positive feedback do not establish recurring revenue or scalable adoption.
- • Leadership-transition costs and execution demands could distract from clinical, regulatory and commercial milestones.
- • HeartBeam remains an early-commercial, loss-making micro-cap facing uncertain FDA requirements, an unstarted pivotal study, limited demonstrated revenue and substantial financing risk.
Catalyst clock
2026-10-31
ALIGN-ACS results at TCT 2026
Lead driver: Sentiment · See AI snapshot
Momentum
100
9% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
37
28% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
+0.2
Sentiment
94
62% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade A. Momentum 99.9 / Value 36.6 / Sentiment 93.5
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-09-11. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$0.50
Analysis reference price unavailable
Analysis 2026-09-11 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$0.20
Analysis reference price unavailable
Analysis 2026-09-11 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$28.18M
Beta
-0.79
Shares Out
56.35M
P/E (TTM) · Derived
-0.8
P/S (TTM)
-
P/FCF (TTM) · Derived
-1.43
Rev YoY
-
EPS YoY
-35.0%
Gross Margin
-
Op Margin
-
Net Debt
-$4.38M
Current Ratio
3.66
As of 2026-09-10 • Updated nightlySource: Internal modelMethods & Data